UCH-L3 Expression in Epithelial Ovarian Cancer and Its Clinical Significance

LI Ting-ting; WANG Hong-jing

Volume 50 Issue 4

Jul. 2019

Turn off MathJax

Article Contents

Abstract

References

JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) > 2019 > 50(4): 556-560.

LI Ting-ting, WANG Hong-jing. UCH-L3 Expression in Epithelial Ovarian Cancer and Its Clinical Significance[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(4): 556-560.

Citation:

LI Ting-ting, WANG Hong-jing. UCH-L3 Expression in Epithelial Ovarian Cancer and Its Clinical Significance[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(4): 556-560.

Citation:

LI Ting-ting, WANG Hong-jing. UCH-L3 Expression in Epithelial Ovarian Cancer and Its Clinical Significance[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(4): 556-560.

PDF (794 KB)

UCH-L3 Expression in Epithelial Ovarian Cancer and Its Clinical Significance

LI Ting-ting^{1, 2},
WANG Hong-jing^{1, 2, ,}

1.
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China
2.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China

More Information

Corresponding author:
WANG Hong-jing, E-mail:whjscdx@163.com
Received Date: November 16, 2018
Revised Date: January 14, 2019
Available Online: March 16, 2021
Published Date: July 19, 2019

Abstract

Abstract

Objective To study the expression of ubiquitin C-terminal hydrolase-L3 (UCH-L3) in epithelial ovarian cancer (EOC) tissues, and to analyze the relationship between UCH-L3 expression and the clinic pathological characteristics and prognosis of EOC patients.
Methods Immunohistochemical analysis was performed to evaluate UCH-L3 expression in different ovarian epithelial tissue specimens. The correlation between UCH-L3 expression and clinical pathologic parameters, prognosis and of EOC was statistically analyzed.
Results The expression level of UCH-L3 in EOC was higher than that in benign ovarian tumor and normal ovary (P < 0.05). The positive expression level of UCH-L3 in late FIGO group, high-level group, group with intraperitoneal metastasis were significantly higher than that in early FIGO group (P=0.006), low-level group (P=0.001), group without intraperitoneal metastasis (P=0.032). There was no significant difference in survival time between the high and low expression groups of UCH-L3.
Conclusion UCH-L3 may play a role in EOC pathogenesis and progression.
- UCH-L3,
- Epithelial ovarian cancer,
- Immunohistochemistry,
- Clinical significance,
- Prognosis

FullText(HTML)

References (21)

References

[1]	SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1):9-29. DOI: 10.3322/caac.21208
[2]	LISA H. Ovarian cancer: multimodal screening keeping mortality at bay? Nat Rev Clin Oncol, 2016, 13(3): 133[2018-04-21]. https://www.nature.com/articles/nrclinonc.2016.10. doi: 10.1038/nrclinonc.2016.10.
[3]	ZHU Z, MU Y, QI C, et al. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro. Int J Mol Med, 2015, 35(2):340-348. DOI: 10.3892/ijmm.2014.2041
[4]	NEUTZNER M, NEUTZNER A. Enzymes of ubiquitination and deubiquitination. Essays Biochem, 2012, 52: 37-50[2018-04-21].http://essays.biochemistry.org/content/52/37.doi:10.1042/bse0520037.
[5]	SINGHAL S, TAYLOR MC, BAKER RT. Deubiquitylating enzymes and disease. BMC Biochem, 2008, 9(Suppl 1): S3[2018-04-21].https://doi.org/10.1186/1471-2091-9-S1-S3.
[6]	KATZ EJ, ISASA M, CROSAS B. A new map to under- stand deubiquitination. Biochem Soc Trans, 2010, 38(Pt 1):21-28. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM20074029
[7]	KIM JH, PARK KC, CHUNG SS, et al. Deubiquitinating enzymes as cellular regulators. J Biochem, 2003, 134(1):9-18. http://cn.bing.com/academic/profile?id=a589967e120d8b46d211f0a94d2b961c&encoded=0&v=paper_preview&mkt=zh-cn
[8]	REYES-TURCU FE, VENTII KH, WILKINSON KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem, 2009, 78: 363-397[2018-04-21].https://doi.org/10.1146/annurev.biochem.78.082307.091526.
[9]	郑旸, 师永红.泛素羧基末端水解酶L3及其与疾病和肿瘤的相关性.临床与病理杂志, 2016, 36(8):1208-1211. http://d.old.wanfangdata.com.cn/Periodical/gwyx-slblkxylcfc201608031
[10]	SCHOBER AS, BERRA E. DUBs, new members in the hypoxia signaling clUb. Front Oncol, 2016, 6: 53[2018-04-21]. https://doi.org/10.3389/fonc.2016.00053.
[11]	YING F, XIZHONG S. Ubiquitin carboxyl-terminal hydrolases:involvement in cancer progression and clinical implications. Cancer Metastasis Rev, 2017, 36(4):669-682. DOI: 10.1007/s10555-017-9702-0
[12]	LIN MT, BEAL MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006, 443(7113):787-795. DOI: 10.1038/nature05292
[13]	KUNTIN L, LEI L, YUNHUI L, et al. A phosphyorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes Dev, 2016, 30(23):2581-2595. DOI: 10.1101/gad.289439.116
[14]	THIERY JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2002, 2(6):442-454. DOI: 10.1038/nrc822
[15]	SONG HM, LEE JE, KIM JH. Ubiquitin C-terminal hydrolase-L3 regulates EMT process and cancer metastasis in prostate cell lines. Biochem Biophys Res Commun, 2014, 452(3):722-727. DOI: 10.1016/j.bbrc.2014.08.144
[16]	ROLÉN U, KOBZEVA V, GASPARIJAN N, et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog, 2006, 45(4):260-269. DOI: 10.1002/mc.20177
[17]	MIYOSHI Y, NAKAYAMA S, TORIKOSHI Y, et al. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci, 2006, 97(6):523-529. DOI: 10.1111/j.1349-7006.2006.00202.x
[18]	STACEY L, RACHEL B, CHRISTOPHER J, et al. Resistance to therapy caused by intragenic deletion in BRCA2.Nature, 2008, 451(7182):1111-1115. DOI: 10.1038/nature06548
[19]	MAXWELL KN, WUBBENHORST B, WENZ BM, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun, 2017, 8(1): 319[2018-04-21]. https://www.nature.com/articles/s41467-017-00388-9.doi:10.1038/s41467-017-00388-9.
[20]	沈铿.复发性卵巢癌的诊断和治疗策略.现代妇产科进展, 2005, 4(3):177-180. DOI: 10.3969/j.issn.1004-7379.2005.03.003
[21]	HOLSCHNEIDER CH, BEREK JS. Ovarian cancer:epidemiology, biology, and prognostic factors. Semin Surg Oncol, 2000, 19(1):3-10. DOI: 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S